EGFR and neoplasm: Operable patients with EGFR CNG positive tumours (high polysomy or amplification) had shorter median overall survival (284 days, 95% CI 284.5–737.5) than patients with EGFR CNG negative tumours (905 days 95% CI 566.9–1243.1), HR 1.51, 95% CI 1.09–2.12, p = 0.016).